For me this was an almost flawless report. EOS delivered its first profitable half, lifted guidance well beyond what most had modelled, and gave far more disclosure than usual on production capacity, the Abrams sequencing and the Dutch programme. MARSS has clearly exceeded what anyone expected in January, and the bank guarantee in the subsequent events section points to a contract that would be the largest in company history.
The issues I raised are worth noting but none of them change my conviction. The R500 opportunity shrinking and slipping is a reminder that management timelines run optimistic, which is not new information. Operating cash flow remaining negative is what you would expect from a company scaling production and building inventory ahead of delivery. Space going backwards is irrelevant at this stage of that segment's development.
The one thing I am genuinely dissatisfied with is the handling of the supply chain question. Montega cut their price target in July specifically because of component availability, and that was the single biggest open question going into this report. Management was asked about it directly and still evaded it to a large extent, pointing to contract lumpiness and delivery timing before acknowledging that EOS continues to manage capacity and supply chain constraints. That is not an answer. Either the constraints are material to the second half or they are not, and management chose not to say which.
Given how much of the investment case now rests on converting a A$846m order book into revenue, I would have expected a clearer explanation. It is the question I would most like answered before the next update.